Fondaparinux is associated with substantially less major bleeding and vascular access site complications compared with enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the OASIS 5 trial
Publication
, Conference
Mehta, SR; Bassand, JP; Granger, CB; Widimsky, P; Steg, PG; Rupprecht, HJ; Faxon, DP; Afzal, R; Chrolavicius, S; Meeks, B; Fox, KAA; Yusuf, S
Published in: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
2006
Duke Scholars
Published In
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ISSN
0735-1097
Publication Date
2006
Volume
47
Issue
4
Start / End Page
205A / 205A
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Mehta, S. R., Bassand, J. P., Granger, C. B., Widimsky, P., Steg, P. G., Rupprecht, H. J., … Yusuf, S. (2006). Fondaparinux is associated with substantially less major bleeding and vascular access site complications compared with enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the OASIS 5 trial. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (Vol. 47, pp. 205A-205A).
Mehta, S. R., J. P. Bassand, C. B. Granger, P. Widimsky, P. G. Steg, H. J. Rupprecht, D. P. Faxon, et al. “Fondaparinux is associated with substantially less major bleeding and vascular access site complications compared with enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the OASIS 5 trial.” In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 47:205A-205A, 2006.
Mehta SR, Bassand JP, Granger CB, Widimsky P, Steg PG, Rupprecht HJ, et al. Fondaparinux is associated with substantially less major bleeding and vascular access site complications compared with enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the OASIS 5 trial. In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2006. p. 205A-205A.
Mehta, S. R., et al. “Fondaparinux is associated with substantially less major bleeding and vascular access site complications compared with enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the OASIS 5 trial.” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 47, no. 4, 2006, pp. 205A-205A.
Mehta SR, Bassand JP, Granger CB, Widimsky P, Steg PG, Rupprecht HJ, Faxon DP, Afzal R, Chrolavicius S, Meeks B, Fox KAA, Yusuf S. Fondaparinux is associated with substantially less major bleeding and vascular access site complications compared with enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the OASIS 5 trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2006. p. 205A-205A.
Published In
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ISSN
0735-1097
Publication Date
2006
Volume
47
Issue
4
Start / End Page
205A / 205A
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology